1.
Zhou S, Deng M, Bian X, Shi J, Liang R, Tao M. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma: Role of ADRB2 and mTOR/PI3K/AKT in LUAD. Cell Mol Biol (Noisy-le-grand) [Internet]. 2024 Feb. 29 [cited 2024 May 20];70(2):120-7. Available from: http://cellmolbiol.org/index.php/CMB/article/view/5253